摘要
目的:观察黄芪糖蛋白(Huang Qi Glycoprotein,HQGP)对肺纤维化小鼠的治疗作用,并初步探讨其作用机制。方法:选取60只健康ICR小鼠,随机分为对照组、模型组及观察组,每组20只。采用鼻腔滴入博莱霉素建立小鼠肺纤维化模型,造模次日起观察组每天每只小鼠腹腔注射HQGP,连续14 d,模型组及对照组腹腔注射等体积的生理盐水;给药后第7、28天每组分别处死5只动物,取肺组织,评价HQGP对肺组织病理形态、肺系数、肺组织羟脯氨酸(Hyp)、超氧化物歧化酶(SOD)、丙二醛(MDA)及转化生长因子-β_1(TGF-β_1)表达的影响。结果:与模型组比较,第7、28天HQGP观察组小鼠的肺纤维化程度减轻,肺组织的TGF-β_1、Hyp、MDA水平显著降低,差异有统计学意义(P<0.05),肺组织SOD水平及肺系数显著升高,差异有统计学意义(P<0.05)。结论:HQGP可能通过降低胶原合成,提高机体的抗氧化能力,对肺纤维化的发生发展起到治疗作用。
Objective To observe the therapeutic effect of Huang Qi Glycoprotein （HQGP） on pulmonary fibrosis mice and discusse the mechanism of action. Methods： A total of 60 healthy ICR mice were randomly divided into the control group, the model group and the treatment group, with 20 mice in each group.The mouse pulmonary fibrosis model was established by intranasal instillation of bleomycin.From the next day, the treatment group was intraperitoneally injected with HQGP for 14 days.The model group and the control group were injected with equal volume of normal saline intraperitoneally; 7, 28 days after giving the drug, each group were sacrificed at 5 animal lung tissue.The effect of HQGP on the changes of the lung pathology, pulmonary index, the content of hydroxyproline （Hyp）, superoxide dismutase （SOD）, malondialdehyde （MDA） and transforming growth factor beta （TGF-β1） were observed. Results： Compared with the model group, the levels of pulmonary fibrosis in mice treated with HQGP were reduced in the 7th and 28th day.The levels of TGF-β1, Hyp, and MDA in lung tissue were significantly lower （ P 〈0.05, P 〈0.01）, and lung tissue SOD and pulmonary index increased significantly （ P 〈0.05, P 〈0.01）. Conclusion： HQGP may play an important role in the development of pulmonary fibrosis by reducing the synthesis of collagen and enhancing the antioxidant capacity of the body.
作者
栾智华
任晋宏
薛慧清
柴智
魏砚明
陈薛静
陈晨
刘新洁
Luan Zhihua;Ren Jinhong;Xue Huiqing;Chai Zhi;Wei Yanming;Chen Xuejing;Chen Chen;Liu Xinjie(Experiment Center,Shanxi University of Traditional Chinese Medicine,Jinzhong 030619,China)
出处
《世界中医药》
CAS
2018年第9期2276-2280,共5页
World Chinese Medicine
基金
国际科技合作专项(2013DFA30700)
山西省黄芪资源产业化及产业国际化协同创新中心项目(HQXTCXZX2016-027)
山西省卫计委科研项目(201601104)
山西中医药大学博士科研启动金项目(2015BK15)
作者简介
栾智华（1979.09-），女，博士，高级实验师，研究方向：中药治疗肺纤维化，E-mail：314538928@qq.com;通信作者：薛慧清（1962.04-），女，博士，教授，硕士研究生导师，研究方向：中药及天然药物化学成分的提取分离，E-mail：xuehuiqing@sina.com;;柴智（1979.07-），男，博士，副教授，硕士研究生导师，研究方向：方药药效及其作用机制，E-mail：chaizhi008@126.com
